| Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. | |
| | |
MedLine Citation:
|
PMID: 18503395 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
STUDY OBJECTIVE: To determine the efficacy of a single 7.5-mg dose of rasburicase compared with single doses of 0.15 mg/kg for the prevention or treatment of hyperuricemia associated with tumor lysis syndrome. DESIGN: Prospective, open-label study using a historical control group. SETTING: Large, nonprofit community teaching hospital. PATIENTS: Seventeen hospitalized patients with cancer and hyperuricemia or a risk for hyperuricemia in the prospective group, and 23 control subjects with cancer who received a weight-based dose of rasburicase. INTERVENTION: Patients in the prospective group received a single 7.5-mg dose of rasburicase and were followed for a minimum of 96 hours. Control subjects received a single 0.15-mg/kg dose of rasburicase. MEASUREMENTS AND MAIN RESULTS: Uric acid levels were measured in all patients at baseline, at 12 and 24 hours after dosing, and then daily. In all patients receiving 7.5 mg, uric acid levels returned to normal at 12 and 24 hours. Mean uric acid levels were similar between the 7.5-mg and 0.15-mg/kg groups at 12 hours (1.9 vs 0.99 mg/dl, p=0.12) and at 24 hours (1.34 vs 1.69 mg/dl, p=0.64). Mean reductions in uric acid levels in the 7.5-mg and 0.15-mg/kg groups were, respectively, 82% and 91% at 12 hours (p=0.04) and 87% and 79% at 24 hours (p=0.35). If 26 doses of rasburicase were administered every year, a 7.5-mg dose would save $41,000/year compared with a 0.15-mg/kg dose ($15,750/10 patients treated). CONCLUSIONS: A single 7.5-mg intravenous dose of rasburicase appeared to have effects similar to those of a single 0.15-mg/kg intravenous dose for the treatment or prevention of hyperuricemia associated with tumor lysis syndrome. This low fixed dose also has the potential to reduce costs. |
| | |
Authors:
|
David J Reeves; Daniel J Bestul |
Related Documents
:
|
9254075 - Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. 14739125 - Raising high-density lipoprotein in humans through inhibition of cholesteryl ester tran... 20596715 - Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome ... 7986315 - Effect of fluvastatin on plasma apolipoprotein-b-containing particles, including lipopr... 10898675 - Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592u89) from a d... 8588065 - An ethologically based, stimulus and gender-sensitive nonhuman primate model for anxiety. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pharmacotherapy Volume: 28 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-05-27 Completed Date: 2009-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 685-90 Citation Subset: IM |
Affiliation:
|
Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Humans Hyperuricemia / drug therapy* Male Middle Aged Prospective Studies Tumor Lysis Syndrome / drug therapy* Urate Oxidase / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
EC 1.7.3.3/Urate Oxidase; EC 1.7.3.3./rasburicase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Laparoscopic-assisted colostomy in children.
Next Document: Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.